Show simple item record

dc.contributor.authorTopkan, Erkan
dc.date.accessioned2019-06-20T09:05:50Z
dc.date.available2019-06-20T09:05:50Z
dc.date.issued2016
dc.identifier.issn2305-5839
dc.identifier.urihttp://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC5075850&blobtype=pdf
dc.identifier.urihttp://hdl.handle.net/11727/3623
dc.description.abstractWeight loss (WL), as a key step of the irreversible and fatal cancer-related anorexia cachexia syndrome is present to some degree in 80% of non-small cell lung cancer (NSCLC) patients upon diagnosis which has been clearly proved to negatively alter patients' performance status, quality of life (QOL), response to treatment, and prognosis. However, WL is not a problem encountered only upon diagnosis but is also commonly reported during the course of aggressive chemotherapy, radiotherapy (RT) and particularly the concurrent chemoradiotherapy (C-CRT) which may further diminish QOL measures and clinical outcomes. In general, the NSCLC literature has concentrated on WL during the treatment course, but recent studies have demonstrated that it is possible to preserve or even experience weight gain (WG) during or just short after the discontinuation of various cancer treatments in approximately 40% to 45% NSCLC patients. Considering the fact that recent evidence suggest a prognostic and predictive role for WG in anticipation of longer survival times and better response rates in weight gainers, this current manuscript will specifically aim to realize the actual value of WG in locally advanced and metastatic NSCLC patients which may potentially be added to the conventional prognostic and predictive factors as a novel surrogate marker of outcomes in such patients.en_US
dc.language.isoengen_US
dc.relation.isversionof10.21037/atm.2016.09.33en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectWeight gain (WG)en_US
dc.subjectCancer treatmenten_US
dc.subjectNon-small cell lung cancer (NSCLC)en_US
dc.subjectPrognosisen_US
dc.titleWeight gain as a surrogate marker of longer survival in advanced non-small cell lung cancer patientsen_US
dc.typearticleen_US
dc.relation.journalANNALS OF TRANSLATIONAL MEDICINEen_US
dc.identifier.volume4en_US
dc.identifier.issue19en_US
dc.identifier.wos000390032300020


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record